EF Hutton analyst Tony Butler initiated coverage of Crispr Therapeutics with a Buy rating and $75 price target. Crisper is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases, Butler tells investors in a research note. The analyst says the company’s portfolio "envelops a broad range of diseases," including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics appoints Harding as SVP, Head of Business Development
- CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
- Crispr Therapeutics provides update on ongoing Phase 1 CARBON trial
- CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
- Oppenheimer emerging biotech analysts to hold analyst/industry conference call
